Non-specific Effects of Rabies Vaccine

PHASE4CompletedINTERVENTIONAL
Enrollment

546

Participants

Timeline

Start Date

August 29, 2018

Primary Completion Date

July 27, 2020

Study Completion Date

July 27, 2020

Conditions
Influenza-like IllnessUpper Respiratory DiseaseDiarrheaFever
Interventions
BIOLOGICAL

Rabivax-S

Rabivax-S is a lyophilized vaccine manufactured by Serum Institute of India Pvt. Ltd. containing inactivated purified rabies antigen (Pitman Moore, PM3218 as virus strain) produced using Vero ATCC CCL 81 cells. The diluent (sterile water for injection) is provided in a separate 1 mL ampoule. After reconstitution, a single dose of 1 mL contains an inactivated, purified rabies antigen (not less than 2.5 IU), glycine (40 mg), sucrose (40 mg) and human serum albumin (25% 10 mg).

DRUG

Sterile Water Injection

The vaccine diluent (sterile water for injection) is provided in a separate 1 mL ampoule.

Trial Locations (1)

Unknown

Ross University School of Veterinary Medicine, Basseterre

All Listed Sponsors
collaborator

Serum Institute of India Pvt. Ltd.

INDUSTRY

lead

Ross University School of Veterinary Medicine

OTHER

NCT03656198 - Non-specific Effects of Rabies Vaccine | Biotech Hunter | Biotech Hunter